miR-126 was shown to downregulate NFκB-mediated PI3K/AKT/mTOR signaling (63) and PI3K inhibition has been implicated as a therapeutic target to inhibit tumor angiogenesis in multiple malignancies (64). Here, NFKB1 is linked to neoplasm.